Related Experiment Video
Updated: Jul 29, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab for endometriosis: Unlikely translatability from oncology due to safety concerns?
Fabio Barra1, Umberto Perrone2, Simone Ferrero3
1Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"- ASL4, Metropolitan Area of Genoa, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Abstract:
This letter discusses the article "The Effects of Rituximab on Experimental Endometriosis Model in Rats" by Dogan et al., which evaluated the potential therapeutic efficacy of rituximab in an experimental animal model of endometriosis. While the study showed promising results in decreasing the volume of endometriotic implants and differences in B-cell count and fibrosis score, rituximab is typically used as a therapy for B lymphocyte malignancies and has potential short-term and long-term side effects. Additionally, animal models for endometriosis have limitations, and novel models are still being developed. Therefore, further preclinical research is necessary to evaluate the safety and efficacy of rituximab as a potential treatment for endometriosis in humans.
